Abstract
Most studies of the neurobiology of schizophrenia have focused on neurotransmitter systems, their receptors, and downstream effectors. Recent evidence suggests that it is no longer tenable to consider neurons and their functions independently of the glia that interact with them. Although astrocytes have been viewed as harbingers of neuronal injury and CNS stress, their principal functions include maintenance of glutamate homeostasis and recycling, mediation of saltatory conduction, and even direct neurotransmission. Results of studies of astrocytes in schizophrenia have been variable, in part because of the assessment of single and not necessarily universal markers and/or assessment of non-discrete brain regions. We used laser capture microdissection to study three distinct partitions of the anterior cingulate gyrus (layers I–III, IV–VI, and the underlying white matter) in the brains of 18 well-characterized persons with schizophrenia and 21 unaffected comparison controls. We studied the mRNA expression of nine specific markers known to be localized to astrocytes. The expression of astrocyte markers was not altered in the superficial layers or the underlying white matter of the cingulate cortex of persons with schizophrenia. However, the expression of some astrocyte markers (diodinase type II, aquaporin-4, S100β, glutaminase, excitatory amino-acid transporter 2, and thrombospondin), but not of others (aldehyde dehydrogenase 1 family member L1, glial fibrillary acidic protein, and vimentin) was significantly reduced in the deep layers of the anterior cingulate gyrus. These findings suggest that a subset of astrocytes localized to specific cortical layers is adversely affected in schizophrenia and raise the possibility of glutamatergic dyshomeostasis in selected neuronal populations.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Arion D, Horvath S, Lewis DA, Mirnics K (2010). Infragranular gene expression disturbances in the prefrontal cortex in schizophrenia: signature of altered neural development? Neurobiol Dis 37: 738–746.
Arnold SE, Franz BR, Trojanowski JQ, Moberg PJ, Gur RE (1996). Glial fibrillary acidic protein-immunoreactive astrocytosis in elderly patients with schizophrenia and dementia. Acta Neuropathol (Berl) 91: 269–277.
Arnold SE, Trojanowski JQ, Gur RE, Blackwell P, Han LY, Choi C (1998). Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch Gen Psychiatry 55: 225–232.
Barradas PC, Ferraz AS, Ferreira AA, Daumas RP, Moura EG (2000). 2′3′Cyclic nucleotide 3′phosphodiesterase immunohistochemistry shows an impairment on myelin compaction in hypothyroid rats. Int J Dev Neurosci 18: 887–892.
Barres BA (2008). The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 60: 430–440.
Bauer D, Gupta D, Harotunian V, Meador-Woodruff JH, McCullumsmith RE (2008). Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia. Schizophr Res 104: 108–120.
Bauer D, Gupta D, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE (2010). Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia. Schizphr Res 117: 92–98.
Benes FM, Bird ED (1987). Spatial arrangement of neurons in cingulate cortex of schizophrenics. Arch Gen Psychiatry 44: 608–616.
Bernstein HG, Steiner J, Bogerts B (2009). Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Rev Neurother 9: 1059–1071.
Bruneau EG, McCullumsmith RE, Haroutunian V, Davis KL, Meador-Woodruff JH (2005). Increased expression of glutaminase and glutamine synthetase mrna in the thalamus in schizophrenia. Schizophr Res 75: 27–34.
Byne W, Dracheva S, Chin B, Schmeidler JM, Davis KL, Haroutunian V (2008). Schizophrenia and sex associated differences in the expression of neuronal and oligodendrocyte specific genes in individual thalamic nuclei. Schizo Res 98: 118–128.
Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS et al (2008). A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci 28: 264–278.
Clinton SM, Meador-Woodruff JH (2004). Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities. Schizophr Res 69: 237–253.
Davidson M, Harvey PD, Powchik P, Parrella M, White L, Knobler HY et al (1995). Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry 152: 197–207.
Dracheva S, Byne W, Chin B, Haroutunian V (2008). Ionotropic glutamate receptor mRNA expression in the human thalamus: Absence of change in schizophrenia. Br Res 1214: 23–34.
Dracheva S, Marras SA, Elhakem SL, Kramer FR, Davis KL, Haroutunian V (2001). N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry 158: 1400–1410.
Dracheva S, McGurk SR, Haroutunian V (2005). mRNA expression of AMPA receptors and AMPA receptor binding proteins in the cerebral cortex of elderly schizophrenics. J Neurosci Res 79: 868–878.
Falke E, Han LY, Arnold SE (2000). Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia. Psychiatry Res 93: 103–110.
Gluck MR, Thomas RG, Davis KL, Haroutunian V (2002). Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. Am J Psychiatry 159: 1165–1173.
Halassa MM, Fellin T, Haydon PG (2007). The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med 13: 54–63.
Haroutunian V, Katsel P, Dracheva S, Stewart DG, Davis KL (2007). Variations in oligodendrocyte-related gene expression across multiple cortical regions: implications for the pathophysiology of schizophrenia. Int J Neuropsychopharmacol 10: 565–573.
Harrison PJ, Weinberger DR (2004). Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10: 40–68.
Harvey PD, Howanitz E, Parrella M, White L, Davidson M, Mohs RC et al (1998). Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry 155: 1080–1086.
Haznedar MM, Buchsbaum MS, Hazlett EA, Shihabuddin L, New A, Siever LJ (2004). Cingulate gyrus volume and metabolism in the schizophrenia spectrum. Schizophr Res 71: 249–262.
Huerta B, McCullumsmith RE, Haroutunian V, Gimenez-Amaya JM, Meador-Woodruff JH (2006). Expression of excitatory amino acid transporter interacting protein transcripts in the thalamus in schizophrenia. Synapse 59: 394–402.
Javitt DC (2007). Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78: 69–108.
Kenakin T (2002). Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42: 349–379.
Krystal JH, Moghaddam B, Breier A, Goldman-Rakic PS, McElvey J (1998). Glutamate, dopamine, the frontal cortex, and schizophrenia. Biol Psychiatry 43: 60S.
Lauriat TL, Dracheva S, Chin B, Schmeidler J, McInnes LA, Haroutunian V (2006). Quantitative analysis of glutamate transporter mRNA expression in prefrontal and primary visual cortex in normal and schizophrenic brain. Neuroscience 137: 843–851.
Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM et al (1991). The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479–486.
Mountcastle V (1997). The columnar organization of the neocortex. Brain 120: 701–722.
Purohit DP, Perl DP, Haroutunian V, Powchik P, Davidson M, Davis KL (1998). Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry 55: 205–211.
Ritter LM, Meador-Woodruff JH (1997). Antipsychotic regulation of hippocampal dopamine receptor messenger RNA expression. Biol Psychiatry 42: 155–164.
Schnieder TP, Dwork AJ (2011). Searching for neuropathology: gliosis in schizophrenia. Biol Psychiatry 69: 134–139.
Steffek AE, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH (2008). Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizo Res 103: 71–82.
Steiner J, Bernstein HG, Bielau H, Farkas N, Winter J, Dobrowolny H et al (2008). S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. J Psychiatr Res 42: 868–876.
Stevens CD, Altshuler LL, Bogerts B, Falkai P (1988). Quantitative study of gliosis in schizophrenia and Huntington's chorea. Biol Psychiatry 24: 697–700.
Stevens JR (1982). Neuropathology of schizophrenia. Arch Gen Psychiatry 39: 1131–1139.
Swanson RA, Ying W, Kauppinen TM (2004). Astrocyte influences on ischemic neuronal death. Curr Mol Med 4: 193–205.
Toro CT, Hallak JE, Dunham JS, Deakin JF (2006). Glial fibrillary acidic protein and glutamine synthetase in subregions of prefrontal cortex in schizophrenia and mood disorder. Neurosci Lett 404: 276–281.
Tunbridge EM, Eastwood SL, Harrison PJ (2010). Changed relative to what? Housekeeping genes and normalization strategies in human brain gene expression studies. Biol Psychiatry 69: 173–179.
Wang L, Metzak PD, Honer WG, Woodward TS (2010). Impaired efficiency of functional networks underlying episodic memory-for-context in schizophrenia. J Neurosci 30: 13171–13179.
Watts J, Thomson AM (2005). Excitatory and inhibitory connections show selectivity in the neocortex. J Physiol 562: 89–97.
Webster MJ, O'Grady J, Kleinman JE, Weickert CS (2005). Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 133: 453–461.
Yang Y, Gozen O, Watkins A, Lorenzini I, Lepore A, Gao Y et al (2009). Presynaptic regulation of astroglial excitatory neurotransmitter transporter GLT1. Neuron 61: 880–894.
Zhang Y, Barres BA (2010). Astrocyte heterogeneity: an underappreciated topic in neurobiology. Curr Opin Neurobiol 20: 588–594.
Acknowledgements
Supported by: MH064673, VA-Merit, and VA-MIRECC.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Katsel, P., Byne, W., Roussos, P. et al. Astrocyte and Glutamate Markers in the Superficial, Deep, and White Matter Layers of the Anterior Cingulate Gyrus in Schizophrenia. Neuropsychopharmacol 36, 1171–1177 (2011). https://doi.org/10.1038/npp.2010.252
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2010.252
Keywords
This article is cited by
-
Astrocytes in human central nervous system diseases: a frontier for new therapies
Signal Transduction and Targeted Therapy (2023)
-
Antipsychotic drug use complicates assessment of gene expression changes associated with schizophrenia
Translational Psychiatry (2023)
-
Up-Regulation of S100 Gene Family in Brain Samples of a Subgroup of Individuals with Schizophrenia: Meta-analysis
NeuroMolecular Medicine (2023)
-
Reduced anterior insular cortex volume in male heroin addicts: a postmortem study
European Archives of Psychiatry and Clinical Neuroscience (2023)
-
Cerebrospinal fluid flow cytometry distinguishes psychosis spectrum disorders from differential diagnoses
Molecular Psychiatry (2021)
